The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. 2008

Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, Winnipeg, MB, Canada R3T 2N2. B_Hasinoff@UManitoba.ca

Anticancer drugs that bind to DNA and inhibit DNA-processing enzymes represent an important class of anticancer drugs. In order to find stronger DNA binding and more potent cytotoxic compounds, a series of ester-coupled bisanthrapyrazole derivatives of 7-chloro-2-[2-[(2-hydroxyethyl)methylamino]ethyl]anthra[1,9-cd]pyrazol-6(2H)-one (AP9) were designed and evaluated by molecular docking techniques. Because the anthrapyrazoles are unable to be reductively activated like doxorubicin and other anthracyclines, they should not be cardiotoxic like the anthracyclines. Based on the docking scores of a series of bisanthrapyrazoles with different numbers of methylene linkers (n) that were docked into an X-ray structure of double-stranded DNA, five bisanthrapyrazoles (n=1-5) were selected for synthesis and physical and biological evaluation. The synthesized compounds were evaluated for DNA binding and bisintercalation by measuring the DNA melting temperature increase, for growth inhibitory effects on the human erythroleukemic K562 cell line, and for DNA topoisomerase IIalpha-mediated cleavage of DNA and inhibition of DNA topoisomerase IIalpha decatenation activities. The results suggest that the bisanthrapyrazoles with n=2-5 formed bisintercalation complexes with DNA. In conclusion, a novel group of bisintercalating anthrapyrazole compounds have been designed, synthesized and biologically evaluated as possible anticancer agents.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009691 Nucleic Acid Denaturation Disruption of the secondary structure of nucleic acids by heat, extreme pH or chemical treatment. Double strand DNA is "melted" by dissociation of the non-covalent hydrogen bonds and hydrophobic interactions. Denatured DNA appears to be a single-stranded flexible structure. The effects of denaturation on RNA are similar though less pronounced and largely reversible. DNA Denaturation,DNA Melting,RNA Denaturation,Acid Denaturation, Nucleic,Denaturation, DNA,Denaturation, Nucleic Acid,Denaturation, RNA,Nucleic Acid Denaturations
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins

Related Publications

Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
July 2009, Bioorganic & medicinal chemistry,
Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
December 2011, Bioorganic & medicinal chemistry,
Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
February 1988, Journal of medicinal chemistry,
Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
January 1997, Journal of medicinal chemistry,
Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
August 2017, Bioorganic & medicinal chemistry letters,
Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
October 2023, Chemical biology & drug design,
Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
April 2020, ChemMedChem,
Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
April 2013, European journal of medicinal chemistry,
Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
May 2014, Journal of computer-aided molecular design,
Brian B Hasinoff, and Hong Liang, and Xing Wu, and Lynn J Guziec, and Frank S Guziec, and Kyle Marshall, and Jack C Yalowich
October 2021, Chemistry (Weinheim an der Bergstrasse, Germany),
Copied contents to your clipboard!